Topline Data on SER-109 Efficacy and Safety From the ECOSPOR III Trial

September 22, 2020
Hosted by Nancy C. Caralla

[Download MP3] [itunes] [Bookmark Episode]

Guest Information

Episode Description

Join us with our guests from Seres Therapeutics as they discuss the latest news on SER-109 and positive topline results from the pivotal Phase 3 ECOSPOR III study evaluating its investigational oral microbiome therapeutic SER-109 for recurrent C. difficile infection (CDI). The study results were equally compelling when characterized by the alternative metric of sustained clinical response, where 88.9% of patients in the SER-109 arm achieved this objective. The study’s efficacy results exceeded the statistical threshold previously provided in consultation with the U.S. Food and Drug Administration (FDA) that could allow this single clinical study to fulfill efficacy requirements for a Biologics License Application (BLA). The SER-109 safety results were favorable, with an adverse event profile comparable to placebo. Listen in and learn more from the leading topic experts.

C. diff. Spores and More

C. diff. Spores and More

Tuesday at 10 AM Pacific Time on VoiceAmerica Health and Wellness Channel

“C. diff. Spores and More” is an educational program providing you with up-to-date information pertaining to C. diff. and Healthcare-Associated infections. Raising awareness through education and advocacy saves lives worldwide. Topics are of C. difficile infection (CDI) prevention, treatments, and environmental safety products along with Healthcare-Associated Infection (HAI) awareness and more. Our guests are topic experts discussing Antibiotic Resistance, Research and Development, Clinical trials, Nutrition Counseling, Microbiome, Mental health, C. diff. survivors, and so much more. Please join us every Tuesday at 10 AM Pacific Time on the VoiceAmerica Health and Wellness Channel.

  • Snag
  • ecard
  • Bookmark and Share
Nancy C. Caralla

Nancy C. Caralla

Nancy C. Caralla, a three time C. diff. survivor, healthcare professional, and now dedicated to “Raising C. diff. Awareness” worldwide. Through the experiences is why we are so passionate raising C. diff. awareness. The C Diff Foundation was brought to fruition in November 2012 with a mission to educate and advocate for C. diff. infection prevention, treatment, and environmental safety worldwide. We now join the many successful hosts and programs on VoiceAmerica to deliver life-saving information through our program; “C. diff. Spores and More.”

  • Snag
  • ecard
  • Bookmark and Share

Episode Directory

November 2020

October 2020

September 2020

  • 9/29/2020: Better Blood Culture Tests Equals Better Patient Care, Fewer Antibiotics, and Less C. difficile Listen Now
  • 9/22/2020: Topline Data on SER-109 Efficacy and Safety From the ECOSPOR III Trial Listen Now
  • 9/15/2020: Encore: Pharmacist Role in C. diff. Stewardship Listen Now
  • 9/8/2020: Pharmacist Role in C. diff. Stewardship Listen Now
  • 9/1/2020: Encore: The Microbiome, C. Diff, and Clinical Trials During COVID-19 Listen Now

This site is protected by Trustwave's Trusted Commerce program